USP and Public Policy
Left
Refine Your Search
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024.
Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024
Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical…
Learn More
USP Global Public Policy Position on advanced manufacturing technologies (AMTs) for medical products. Published in 2024.
Learn More
USP supports comprehensive policies and programs to address AMR, including building capabilities among global stakeholders to reduce the proliferation of poor-quality medicines and advocating and…
Learn More
USP Global Public Policy Position published 2024
Learn More
USP supports a comprehensive public policy framework to combat substandard and falsified medicines, including advancing stewardship of quality pharmaceutical products and practices, and building the…
Learn More
A resilient supply chain withstands acute disruptions so that safe, effective, and quality medicines can be supplied to patients around the globe, in adequate quantities, when they are needed. Poster…
Learn More